Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Heisig, Anne, Sörensen, Jan, Zimmermann, Stefanie-Yvonne, Schöning, Stefan, Schwabe, Dirk, Kvasnicka, Hans-Michael, Schwentner, Raphaela, Hutter, Caroline, Lehrnbecher, Thomas
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2018
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955145/
https://ncbi.nlm.nih.gov/pubmed/29774135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25277
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items